This content is machine translated Incretin mimetics for obesity and prediabetes Liraglutide, semaglutide and tirzepatide: considerable evidence base Weight reduction is an important therapeutic measure in diabetes prevention. Prediabetes is characterized by elevated fasting blood sugar and/or impaired glucose tolerance, but not yet manifest diabetes. In obese people,...…
View Post 4 min This content is machine translated Semaglutide and tirzepatide in HFpEF and T2D/obesity Prospect of improved cardiovascular prognosis Patients suffering from heart failure with preserved ejection fraction (HFpEF) are very often also affected by cardiometabolic comorbidities such as obesity and type 2 diabetes. Although previous randomized trials suggest...…
View Post 3 min This content is machine translated Development of a quintuple agonist New strategy in the fight against obesity and T2D The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists...…
View Post 6 min This content is machine translated Obesity in the family practice Aim for realistic goals and avoid apportioning blame Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the...…
View Post 4 min This content is machine translated Obesity Extent of weight reduction is prognostically relevant According to the World Health Organization (WHO), obesity is one of the greatest health risks. With increasing severity, the risk of various concomitant and secondary diseases increases. Obesity-related multimorbidity is...…
View Post 4 min This content is machine translated Case report: Drug-induced hepatitis Rare side effect of tirzepatide therapy The dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide 1 (GLP1) receptor agonist triazepatide has shown promise for improving glycemic control and weight loss. However, it can also have undesirable side effects....…
View Post 2 min This content is machine translated Tirzepatide after the menopause stage Significant reduction in KG and waist circumference In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the...…
View Post 4 min This content is machine translated Study report: Obesity New findings on the effects of incretin analogs A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy...…
View Post 3 min This content is machine translated Real-world data from tirzepatide Safety comparable to other GLP1-RA As more people with type 2 diabetes (T2D) take medication to control blood sugar levels and lose weight, safety concerns have arisen. Real-world evidence from the US Food and Drug…
View Post 3 min This content is machine translated Tirzepatide for type 2 diabetes Post-hoc analysis of the SURPASS studies The SURPASS study program investigated the efficacy and safety of the dual GIP/GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. An exploratory analysis of the Phase III SURPASS…
View Post 6 min This content is machine translated Incretin-based therapies for type 2 diabetes Evolution of therapy options continues Incretin mimetics are an attractive treatment option, particularly for the subgroup of overweight type 2 diabetics, as they not only have glucose-lowering effects, but have also demonstrated clinical benefits in…
